What is AstraZeneca PLC (AZN.L)?

AstraZeneca PLC (AZN.L) is a stock in the Healthcare sector, Drug Manufacturers - General industry. View full analysis on Stocks360.

AstraZeneca PLC (AZN.L)

Stock analysis · LSE · Healthcare · Drug Manufacturers - General

Market Cap

N/A

PE (TTM)

N/A

EPS (TTM)

N/A

Dividend Yield

N/A

Beta

0.21

Day Range

N/A

52-wk Range

N/A

Avg Volume

N/A

Volume

N/A

AstraZeneca PLC (AZN.L) is a publicly traded company in the Healthcare sector. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Earnings

Most Recent

Jul 27, 2026

EPS $1.98 vs est. $1.87

Beat by $0.11

Proprietary Signals

Signal snapshot temporarily unavailable.

About AstraZeneca PLC

AstraZeneca PLC operates as a biopharmaceutical company, specializing in the discovery, development, manufacturing, and commercialization of prescription medications. Its comprehensive portfolio addresses diverse therapeutic areas. In oncology, key marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex. For cardiovascular, renal, and metabolism diseases, the company offers treatments such as Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR. Respiratory and immunology conditions are targeted by products like Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris. Additionally, rare diseases are treated with Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris. The company's product offerings also extend to Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for influenza; Seroquel IR/Seroquel XR for schizophrenia and bipolar disorder; Nexium and Losec/Prilosec for gastroenterology;…